The potential clinical relevance of this work is highlighted by evidence that combinatorial blockade of TIGIT and other checkpoint receptors also enhances the effector function of ex vivo‐stimulated CD8+ TIL from melanoma patients as well as CD4+ and CD8+ T cells from acute lymphocytic leukemia patients, suggesting that such regimens are likely to show improvements over monotherapies in cancer patients as well.201, 205. This evidence concerns the gene TIGIT and melanoma.